Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
Molecular and Cellular Biology
|
August 2, 2006
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J Griswold, Mary MacPartlin, Thomas Bumm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2023
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Olivia M Lucero, Ji-Ann Lee, Jenna Bowman, et al.
Oncogene
|
July 24, 2019
SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells
Qiao-Yang Sun, Ling-Wen Ding, Kara Johnson, et al.
Blood
|
February 26, 2025
A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia
Basil Allen, Daniel Bottomly, Thomas Köhnke, et al.
Blood Neoplasia
|
April 20, 2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia
Uma Borate, Cristina E Tognon, Yazan F Madanat, et al.
Nature
|
October 19, 2018
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, et al.
Cancer Cell
|
July 22, 2022
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
Daniel Bottomly, Nicola Long, Anna Reister Schultz, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
Molecular and Cellular Biology
|
August 2, 2006
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J Griswold, Mary MacPartlin, Thomas Bumm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2023
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Olivia M Lucero, Ji-Ann Lee, Jenna Bowman, et al.
Oncogene
|
July 24, 2019
SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells
Qiao-Yang Sun, Ling-Wen Ding, Kara Johnson, et al.
Blood
|
February 26, 2025
A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia
Basil Allen, Daniel Bottomly, Thomas Köhnke, et al.
Blood Neoplasia
|
April 20, 2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia
Uma Borate, Cristina E Tognon, Yazan F Madanat, et al.
Nature
|
October 19, 2018
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, et al.
Cancer Cell
|
July 22, 2022
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
Daniel Bottomly, Nicola Long, Anna Reister Schultz, et al.
Page
of 3